The patient ultimately died due to progressive liver failure.<h4>Conclusion</h4>ALK-targeted therapy may provide benefit in selected CRC cases with atypical <i>ALK</i> alterations, even when the oncogenic role is uncertain. This evidence concerns the gene ALK and colorectal carcinoma.